Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U5AQ
|
|||
| Drug Name |
ATLCAR.CD30.CCR4 cells
|
|||
| Drug Type |
CAR T Cell Therapy (Dual specific)
|
|||
| Indication | Immune System disease [ICD-11: 4A01-4B41] | Phase 1 | [1] | |
| Immunoproliferative disorder [ICD-11: 2B32; ICD-10: D47.9] | Phase 1 | [1] | ||
| Lymphatic disease [ICD-11: BD9Z] | Phase 1 | [1] | ||
| Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [1] | ||
| Neoplasm [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | ||
| Company |
UNC Lineberger Comprehensive Cancer Center
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-C chemokine receptor type 4 (CCR4) | Target Info | CAR-T-Cell-Therapy(Dual specific) | [1] |
| Lymphocyte activation antigen CD30 (TNFRSF8) | Target Info | CAR-T-Cell-Therapy(Dual specific) | [1] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| Viral carcinogenesis | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Reactome | Chemokine receptors bind chemokines | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.